What Is 23andMe Holding

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 23andMe holds genetic data from over 12 million customers as of 2023, offering ancestry reports and health predisposition insights based on DNA analysis. The company also shares anonymized data with pharmaceutical partners for research purposes under user consent.

Key Facts

23andMe has collected DNA data from more than 12 million individuals as of 2023
The company offers health reports on over 150 genetic conditions and traits
In 2018, GlaxoSmithKline invested $300 million in a 23andMe research partnership
23andMe received FDA approval for certain health risk reports starting in 2015
Over 80% of customers consent to having their anonymized data used in research

Overview

23andMe is a consumer genetics company that analyzes DNA samples to provide personalized reports on ancestry, health predispositions, and inherited traits. Founded in 2006 by Linda Avey, Paul Cusenza, and Anne Wojcicki, it quickly became a leader in direct-to-consumer genetic testing.

The company collects saliva samples from customers, extracts DNA, and uses genotyping to identify variants linked to specific traits or conditions. Over time, 23andMe has expanded from ancestry-only reports to include FDA-authorized health risk assessments.

Customer base: As of 2023, 23andMe has processed over 12 million DNA kits, making it one of the largest private genomic databases in the world.
Data collection: Each sample provides genotyping data for approximately 600,000 to 700,000 SNPs (single nucleotide polymorphisms) across the genome.
Health reports: The company offers insights into more than 150 conditions, including Parkinson’s, late-onset Alzheimer’s, and BRCA1/BRCA2-related cancer risks.
Research use: 23andMe uses aggregated, de-identified data to power internal and external research, with over 80% of users opting in to research participation.
Regulatory milestones: In 2015, the FDA reversed a previous ban, allowing 23andMe to offer carrier status and health risk reports directly to consumers.

How It Works

23andMe’s service begins with a saliva-based DNA collection kit mailed to customers, followed by lab analysis and digital reporting accessible online. The entire process is designed for accessibility, requiring no medical visit or physician referral.

Saliva collection: Customers provide a saliva sample using a sterile tube, which is shipped back to 23andMe’s lab in Indiana for processing.
DNA extraction: Labs extract DNA from white blood cells in the saliva, then amplify and purify the genetic material for genotyping.
Genotyping: The sample is analyzed using Illumina’s OmniExpress chip, scanning hundreds of thousands of SNPs across the genome.
Data interpretation: Algorithms compare customer genotypes to scientific research databases to generate ancestry composition and trait reports.
Health reporting: For FDA-approved markers, 23andMe reports on genetic risk variants such as those linked to celiac disease or hereditary thrombophilia.
Privacy controls: Users can choose whether to share data anonymously with researchers or pharmaceutical partners, with opt-in consent required.

Comparison at a Glance

Below is a comparison of 23andMe with other major consumer DNA testing services based on data scope, health reporting, and research use.

Service	Database Size	Health Reports	Ancestry Regions	Research Partnerships
23andMe	12 million+	Yes (FDA-approved)	170+ regions	Yes (e.g., GSK, Pfizer)
AncestryDNA	23 million+	No health data	Over 1,000 regions	Limited
MyHeritage DNA	5 million+	Third-party health add-ons	42 regions	No
FamilyTreeDNA	2 million+	No	20+ regions	No
Living DNA	500,000+	Limited wellness reports	80+ regions	No

While AncestryDNA has the largest database, 23andMe is unique in offering FDA-regulated health risk reports and maintaining active pharmaceutical research collaborations. Its focus on medical genetics differentiates it from competitors primarily focused on genealogy.

Why It Matters

23andMe’s vast genetic database has significant implications for public health, medical research, and personal privacy. By aggregating consumer DNA data, the company enables large-scale studies on genetic diseases without traditional clinical trials.

Drug development: 23andMe’s partnership with GlaxoSmithKline in 2018 led to the discovery of new drug targets for autoimmune diseases.
Population health: Research using 23andMe data has identified genetic links to depression, lupus, and endometriosis.
Personal awareness: Users gain early insights into hereditary risks, enabling proactive healthcare decisions and genetic counseling.
Data privacy concerns: Critics highlight risks of re-identification and potential misuse by insurers or law enforcement.
Regulatory precedent: 23andMe helped establish the FDA’s framework for direct-to-consumer genetic testing regulations.
Scientific democratization: The platform allows non-academic researchers and citizen scientists to contribute to genomic discovery.

As genomic data becomes increasingly integrated into healthcare, 23andMe’s model demonstrates both the promise and challenges of consumer-driven genetic research. Its role in bridging personal curiosity with medical advancement continues to shape the future of precision medicine.